Comparative effectiveness and safety of inclisiran versus evolocumab and alirocumab: a 180-day real-world study - PubMed
3 days ago
- #PCSK9 inhibitors
- #lipid-lowering therapy
- #real-world evidence
- All three PCSK9 inhibitors (inclisiran, evolocumab, alirocumab) significantly lowered LDL-C at 180 days with no major differences between groups.
- Inclisiran showed a non-significant numerical advantage in apolipoprotein B (apoB) reduction compared to the monoclonal antibodies.
- Treatment persistence was highest with inclisiran (69.7%), followed by evolocumab (56.1%) and alirocumab (50.0%).
- All therapies were well-tolerated with no new safety signals reported in this real-world study.
- Inclisiran's twice-yearly dosing may offer clinical value through better adherence and a trend toward enhanced apoB suppression.